ETNB 89bio.com Earnings growth forecast for next year
89bio, Inc. develops high-margin therapies for metabolic disorders, providing excellent scaling potential. Shifts in analyst EPS growth estimates reflect market expectations, where -1.80 shapes the current metric. However, stringent FDA oversight and colossal R&D expenditures create significant barriers to entry, while research centers and external laboratories continue to operate strictly on schedule.
ETNB (89bio Inc): analytical breakdowns and indicator data
- share price and consensus valuation forecast:
- market capitalization data:
- book capitalization indicators:
- debt and solvency information:
Total Debt to Capital 89bio, Inc.|ETNB - Ratio of Long-Term Indebtedness to Capital|Short-Term Debt to Equity 89bio Pharma|ETNB - Company Total Debt Obligations|Debt to Book Capitalization Ratio 89bio Corp|ETNB - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 89bio|Quick Ratio 89bio.com
- net income and valuation ratios data:
ETNB - Company Net Income|Projected Future Earnings 89bio, Inc.|ETNB - Business Payback Period|Future Price to Earnings 89bio Pharma|ETNB - Price to Earnings Adjusted for Growth Rate|Enterprise Value to EBITDA Ratio 89bio Corp|ETNB - Income before deduction of interest, taxes and amortization|Net earnings per share (EPS TTM) 89bio|ETNB - Net earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months 89bio.com|ETNB - Earnings per share growth this year|Earnings growth forecast for next year 89bio, Inc.
- total revenue and sales volume data:
Initial company analysis:ETNB, 89bio.com
This indicator reflects the analysts' consensus forecast for the growth rate of earnings per share, making it possible to identify asset overvaluation through a slowdown in expected growth. Professional investors utilize the projected change in earnings per share for the coming year to assess the resilience of 89bio, Inc. (ETNB) to geopolitical risks that could disrupt drug synthesis logistics and clinical trial timelines.
Analysis of competing companies
ASND (Ascendis) - Earnings growth forecast for next year|Earnings growth forecast for next year Madrigal Pharmaceuticals|Earnings growth forecast for next year CORT|Net earnings per share growth forecast for next year RYTM (Rhythm Pharma)|Net earnings per share growth forecast for next year akerotx.com AKRO|Metsera Therapeutics (MTSR) - Expected net earnings per share growth next year|MLTX - Net earnings per share growth forecast for next year|CRNX: Net earnings per share growth forecast for next year|NAMS: Earnings growth forecast for next year|SLNO - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Amicus Corp|Agios Corp (AGIO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year structuretx.com (GPCR)|Expected earnings per share growth for next year mimedx.com MDXG|Net earnings per share growth forecast for next year Rezolute RZLT|Lexicon Pharmaceuticals, Inc. - Net earnings per share growth forecast for next year|MBX: Expected earnings per share growth for next year|Altimmune Corp - Projected earnings per share increase next year|Aardvark Therapeutics Inc (AARD) - Net earnings per share growth forecast for next year|Net earnings per one share growth forecast for next year Sagimet Biosciences SGMT|BIOA (bioagelabs.com) - Earnings growth forecast for next year|Expected earnings per share growth for next year Biomea Fusion (BMEA)|Earnings growth forecast for next year QNCX|Projected earnings per share increase next year GUTS|Earnings growth forecast for next year VTVT (vTv Therapeutics Inc.)|Expected earnings per share trend next year ATPC|Pluristem Therapeutics - Earnings growth forecast for next year|Consensus forecast of earnings per share growth for next year synlogictx.com SYBX|LPCN: Earnings growth forecast for next year|Matinas BioPharma Holdings, Inc. - Expected earnings per share trend next year|SPRB (Spruce Biosciences Inc.) - Earnings growth forecast for next year|galecto.com (GLTO) - Consensus forecast of earnings per share growth for next year|Net earnings per share growth forecast for next year Carmell Therapeutics (CTCX)|LUMO (Lumos Pharma Inc) - Expected earnings per share trend next year|Net earnings per share growth forecast for next year organovo.com ONVO|Radius Health (RDUS) - Expected net earnings per share growth next year
